Semester: Spring
Offered: 2023
Course Description and Assignments
Immunotherapy has revolutionized cancer treatments. It has resulted in complete and durable responses in several malignancies including advanced melanoma and non-small cell lung cancer, among others. However, responses remain heterogeneous among patients, and some experience serious side effects. In this nanocourse, we will discuss the two major types of cancer immunotherapy: checkpoint blockade and engineered T cells. We will discuss the mechanisms of action, the clinical challenges, and potential approaches to further advance the field.
Each of the four sessions will conclude with a ~20-30 min question and discussion, and a brief homework assignment.
Course Director
Mohammad Rashidian PhD, Dana-Farber Cancer Institute